Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Saved in:
| Title: | Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials. |
|---|---|
| Authors: | Pagano G; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. gennaro.pagano@roche.com.; University of Exeter Medical School, London, UK. gennaro.pagano@roche.com., Trundell D; Roche Products Ltd, Welwyn Garden City, UK., Simuni T; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Pavese N; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK., Marek K; Institute for Neurodegenerative Disorders, New Haven, CT, USA., Postuma RB; Department of Neurology, McGill University, and Montreal Neurological Institute, Montreal, Canada., Shariati N; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Monnet A; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Moore E; Roche Products Ltd, Welwyn Garden City, UK., Davies EW; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Svoboda H; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Diagnostics GmbH, Penzberg, Germany., Pross N; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Bonni A; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland., Nikolcheva T; F. Hoffmann-La Roche Ltd, Basel, Switzerland. |
| Corporate Authors: | PASADENA Investigators, Prasinezumab Study Group |
| Source: | NPJ Parkinson's disease [NPJ Parkinsons Dis] 2025 Aug 13; Vol. 11 (1), pp. 241. Date of Electronic Publication: 2025 Aug 13. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 101675390 Publication Model: Electronic Cited Medium: Print ISSN: 2373-8057 (Print) Linking ISSN: 23738057 NLM ISO Abbreviation: NPJ Parkinsons Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40804248 AccessLevel: 2 PubTypeId: unknown PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Pagano+G%22">Pagano G</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. gennaro.pagano@roche.com.; University of Exeter Medical School, London, UK. gennaro.pagano@roche.com.<br /><searchLink fieldCode="AU" term="%22Trundell+D%22">Trundell D</searchLink>; Roche Products Ltd, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Simuni+T%22">Simuni T</searchLink>; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Pavese+N%22">Pavese N</searchLink>; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK.<br /><searchLink fieldCode="AU" term="%22Marek+K%22">Marek K</searchLink>; Institute for Neurodegenerative Disorders, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Postuma+RB%22">Postuma RB</searchLink>; Department of Neurology, McGill University, and Montreal Neurological Institute, Montreal, Canada.<br /><searchLink fieldCode="AU" term="%22Shariati+N%22">Shariati N</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Monnet+A%22">Monnet A</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Moore+E%22">Moore E</searchLink>; Roche Products Ltd, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Davies+EW%22">Davies EW</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Svoboda+H%22">Svoboda H</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Diagnostics GmbH, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Pross+N%22">Pross N</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bonni+A%22">Bonni A</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Nikolcheva+T%22">Nikolcheva T</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22PASADENA+Investigators%22">PASADENA Investigators</searchLink><br /><searchLink fieldCode="CA" term="%22Prasinezumab+Study+Group%22">Prasinezumab Study Group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101675390%22">NPJ Parkinson's disease</searchLink> [NPJ Parkinsons Dis] 2025 Aug 13; Vol. 11 (1), pp. 241. <i>Date of Electronic Publication: </i>2025 Aug 13. – Name: TypePub Label: Publication Type Group: TypPub Data: Published Erratum – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101675390 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2373-8057 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223738057%22">23738057 </searchLink><i>NLM ISO Abbreviation: </i>NPJ Parkinsons Dis <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40804248 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41531-025-01103-y Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 241 Titles: – TitleFull: Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pagano G – PersonEntity: Name: NameFull: Trundell D – PersonEntity: Name: NameFull: Simuni T – PersonEntity: Name: NameFull: Pavese N – PersonEntity: Name: NameFull: Marek K – PersonEntity: Name: NameFull: Postuma RB – PersonEntity: Name: NameFull: Shariati N – PersonEntity: Name: NameFull: Monnet A – PersonEntity: Name: NameFull: Moore E – PersonEntity: Name: NameFull: Davies EW – PersonEntity: Name: NameFull: Svoboda H – PersonEntity: Name: NameFull: Pross N – PersonEntity: Name: NameFull: Bonni A – PersonEntity: Name: NameFull: Nikolcheva T IsPartOfRelationships: – BibEntity: Dates: – D: 13 M: 08 Text: 2025 Aug 13 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 2373-8057 Numbering: – Type: volume Value: 11 – Type: issue Value: 1 Titles: – TitleFull: NPJ Parkinson's disease Type: main |
| ResultId | 1 |